Brought to you by 
Genzyme to buy GelTex in $1bn cash/stock deal
10 Oct 2000
Executive Summary
Genzyme General is buying GelTex for about $1bn--$500mm in cash and $500mm in Genzyme common stock. Each GelTex share will be exchanged for $47.50 in cash or 0.7272 in stock (a premium of 27% based on the price of Genzyme stock at announcement), subject to proration to keep the cash part at 50%.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme to buy GelTex in $1bn cash/stock deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice